At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Innate Pharma announced positive results from its TELLOMAK Phase II study evaluating lacutamab in mycosis fungoides.

Treatment with lacutamab showed clinically significant antitumor activity in heavily pretreated patients, independent of KIR3DL2 expression level, and with a safety profile similar to that previously observed.

"These results are very promising and support the continued development of lacutamab to bring better treatments to patients with cutaneous T-cell lymphomas", comments Medical Director Sonia Quaratino.

Copyright (c) 2024 CercleFinance.com. All rights reserved.